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Abstract
Background: This pilot study was carried out to determine whether Helicobacter pylori can be
detected in normal colon or in association with colorectal neoplasia.
Methods: Paraffin processed colonic tissue blocks of normal colonic mucosa (n = 60), and patients
diagnosed as adenoma (n = 60), and adenocarcinoma (n = 60) were retrieved from our archive; the
adenoma group included tubular (n = 20), tubulovillous (n = 20) and villous adenomas (n = 20). 4
μm sections were stained by immunohistochemical methods using anti-Helicobacter pylori antibodies
(polyclonal NCL-HPp and monoclonal NCL-C-jejuni).
Results: Significant numbers of Helicobacter pylori were identified in tubular adenomas (OR = 11.13;
95%CI = 1.62–76.70), tubulovillous adenomas (OR = 10.45; 95%CI = 1.52–71.52) and
adenocarcinomas (OR = 8.13; 95%CI = 1.40–46.99) compared to controls: there was no
association in numbers of Helicobacter pylori and villous adenomas (OR = 2.95; 95%CI = 0.29–9.96).
Conclusion: We conclude that although, in this pilot study, there appears to be an association in
the prevalence of Helicobacter pylori with some, but not all, colorectal neoplasms, we can not infer
causality from these results. These findings need to be further substantiated with a prospective
study and the use of molecular biological techniques to determine a causal association.
Background
Colorectal cancers develop sequentially from hyperprolif-
erative epithelium and aberrant crypt foci through to ade-
nocarcinomas, passing through an adenomatous stage
[1,2]. These adenomatous foci are neoplastic intraluminal
protuberant, occasionally flat, dysplastic glandular
lesions, represented by tubular or villous adenomas at
either architectural extreme [3]; aetiologically, environ-
mental, social and genetic factors or influences have been
implicated in their genesis [4-7]. The possibility however
of Helicobacter pylori (HP) as an initiator of colorectal neo-
plasia [8,9], similar to its role in gastric carcinoma and
lymphoma [3,10] is subject of investigation. It is well
established that HP is associated with extragastric disease
[11], as are several non-HP species [12,13]; indeed HP has
been identified outwith the stomach [11,14-16], in the
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intestine [14,15,17] as well as in faeces [18]. Most associ-
ations between neoplastic colorectal lesions (adenomas
and carcinomas) and HP are based on studies correlating
these lesions with HP seropositivity [9,19-23] or, indirect
evidence such as increased gastrin [24,25] or CagA+ levels
[24]. Other studies have failed to demonstrate this associ-
ation based on seropositivity [26-28]; indeed it has been
suggested that HP does not colonise rectal mucosa [29].
In this study we have used immunohistochemical meth-
ods to interrogate normal, adenomatous colorectal tissue
and colorectal adenocarcinomas for the presence of HP,
using anti-HP antibodies.
Methods
This pilot study was independently examined and ethi-
cally approved by the Local Research Ethics Committee,
Royal Cornwall Hospital, Cornwall, UK.
Samples of paraffin-embedded colorectal tissue (n = 180)
including normal (n = 60), adenomas (n = 60) and aden-
ocarcinomas (n = 60) were retrieved from departmental
archives. Sixty samples of each diagnosis gave an accepta-
ble precision for the prevalence estimates. This powered
the study at 0.80 (α = 0.05) to detect an absolute differ-
ence of 26% in the prevalence of the different diagnoses.
Specimens were not matched for age, sex or socioeco-
nomic status as it was thought that this would confound
any comparisons; a higher prevalence in adenocarcino-
mas might simply reflect the greater age of the people with
this type of neoplasia. However, the age and sex were
adjusted for using binary logistic regression once the
results had been established. The number of males and
females and their mean ages in each group is shown in
Table 1. Patients included in the normal category had
biopsies for non-specific gastrointestinal symptoms, iron
deficiency investigation or diarrhoea, but whose histology
was unremarkable.
Each sample group of patients was separate and mutually
exclusive. Patients with normal biopsies did not have a
biopsy history of colorectal adenomas or carcinomas, or
other carcinoma. The patient group with adenomas did
not have a biopsy history of colorectal or other carcinoma.
Patients with colorectal adenocarcinoma formed the third
group: these patients did not have a biopsy history of can-
cer at any other site. The limitations of this study include
unavailability of information relating to serology or
breath test or, preceding gastric biopsy.
Since there is a sequential progression of colorectal polyps
to colorectal adenocarcinoma, 20 cases each of tubular,
tubulovillous and villous adenomas were selected. Immu-
nohistochemical techniques were chosen because they are
more specific and sensitive than tinctorial techniques [30-
33].
Cases were identified from the histopathology database
between 1996 and 2001, using appropriate T and M codes
and the relevant paraffin blocks were retrieved. Topo-
graphical code T67*/68* identified biopsies from the
colorectum. Morphology code M00100 identified biop-
sies considered normal; M80400, M82630, M82611 and
M81403 detected adenomas and carcinomas.
Four 4 μm sections were cut from each of the 180 forma-
lin fixed paraffin blocks using a Leica® rotary microtome.
Diagnosis were confirmed with an H/E stain; the other
sections were used for immunohistochemistry. H/E and
immunohistochemistry were used to detect HP organ-
isms; Giemsa was not used. The immunohistochemically
stained slides were randomized, given individual research
numbers and then examined by light microscopy
Two Novocastra®  antibodies were used: 1) polyclonal
NCL-HPp (specific and sensitive for HP; dilution
1:150)[34,35] and, 2) monoclonal NCL-C-jejuni (raised
against campylobacter jejuni; dilution 1:800), which cross-
reacts with HP. The use of two antibodies allowed for
identification and differentiation of HP from Campylo-
bacter in our study material. The strategy was to see
whether we could identify one or the other, using immu-
nohistochemistry on protocol samples.
Antigen retrieval was carried out in a citrate buffer pH6.0
for 30 minutes at 430W in a domestic microwave. This
method was chosen over the Novocastra recommended
trypsin digestion following experiments comparing both
methods, as recommended[34,35]. Positive controls were
gastric biopsies known to be positive for HP; the primary
antibody was omitted in negative controls.
The detection method followed was that provided by
Dako with the ChemMate™ Envision detection kit [36].
The ChemMate™ Envision detection kit was used as the
dextran polymer based secondary antibody technique is a
two step process which is fast, reliable and with superior
sensitivity to the avidin-biotin method [36].
Sections were counterstained using Mayer's Haematoxylin
for 1 minute and blued in Scotts Tap water. Odds ratios
(OR) were estimated using the Logit procedure in SPSS11.
Results
Four cases were excluded from this analysis; two from the
normal tissue group, one from the adenocarcinoma group
and one from the tubular adenoma group. These were due
to inadequate tissue samples.World Journal of Surgical Oncology 2007, 5:51 http://www.wjso.com/content/5/1/51
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HP organisms were golden-brown "dot-like" and granular
against a light blue Haematoxylin counterstain. We were
unable to unequivocally detect the spiral form of HP on
H/E or immunohistochemistry in any of our normal or
neoplastic colonic biopsy samples; we assume from this
that the "granular" HP-positive organisms represented the
coccoid form [37-39] of the organism. Figure 1 shows
positive anti-HP immunohistochemical reactions in con-
trol gastric mucosa with NCL-HPp (Figure 1a &1b). Figure
2 shows colonic mucosa with positive anti-NCL-HPp (Fig-
ure 2a) and anti-NCL-C-jejuni (Figure 2b) immunohisto-
chemistry. The positivity with both antibodies was
convergent; we did not observe positivity of one antibody
without the other also being positive. We concluded from
this that we were observing only HP organisms, rather
than non-HP organisms or other Helicobacter species.
These organisms were luminal[32,40] although a rare
organism was seen in a crypt. Their staining patterns were
similar to that in the stomach although in the latter,
organisms were frequently seen in glandular lumina.
The patient demographics and results are listed in table 1.
There were more females in each group, with the excep-
tion of patients with tubular and tubulovillous adenomas.
HP was detected in only one normal (control) (2%) spec-
imen but between 17 and 21% of patients with colorectal
neoplasia; only 5% of patients with villous adenomas
showed immunoreactivity for HP organisms. Compared
to normal (controls) therefore, significant numbers of HP
are seen in tubular (OR 11.13; 95% Confidence interval
(CI) 1.62–76.60) and tubulo-villous (OR 10.45; 95% CI
1.52–71.52) adenomas and, in adenocarcinoma (OR
8.13; 95% CI 1.40–46.99) but not in villous adenomas
(OR 2.95; 95% CI 0.29–9.96).
Discussion
We have used immunohistochemical methods to demon-
strate that HP organisms do reside in the colorectum asso-
ciated with colorectal neoplasms. Although we can not
attribute a cause-and-effect relationship in this instance,
there is certainly indirect evidence demonstrating this
association[9,19-25,41,42], as there is evidence refuting it
[26-29]. Clearly, the use of serum-based methods can lead
to ambiguous results especially since antibodies can be
detectable a long time after the bacteria have ceased to col-
onise the gut[28].
We used immunohistochemical detection methods rather
than routine histochemistry (Giemsa) as the former are
said to be more accurate[32] and are more likely to detect
non-spiral forms of the organism[31,33,37-39]. However
Giemsa has been reported to be more sensitive for the
detection of spiral gastric forms of the organism[43].
Our results show that the prevalence of HP is significant
in tubular and tubulovillous adenomas but not in villous
adenomas; the reason for this is unclear. It may be that the
microenvironment in villous adenomas does not support
HP in a similar manner to absence of HP in foci of intes-
tinal metaplasia in the stomach[5] or, low HP prevalence
is some types of gastric fundic polyps[44]. The absence of
HP in association with villous adenomas does not neces-
sarily signify an absence of an association but merely that
HP could have migrated away from these polyps after hav-
ing initiated the lesion (if indeed there is such a relation-
ship). This would be analogous to HP migration having
first produced gastric abnormalities[45].
Although some studies have not been able to substantiate
an association between HP and colorectal neoplasia and
HP [26-28] or, that these organisms can colonise the
colon[29,46], we have been able to demonstrate their
presence (using immunohistochemistry) in certain types
of colorectal neoplasia; we have not looked at HP in asso-
ciation with other non-neoplastic epithelial lesions.
Indeed, in one study, 27% of colorectal adenocarcinomas
contained Helicobacter  DNA; however, this study could
not determine a statistical association between its pres-
ence and the different Dukes stages of colorectal adeno-
carcinomas or, between colonic and rectal
adenocarcinomas[41].
HP-induced carcinogenesis is thought to be initiated by
gastrin-induced genomic instability (gastrin hypersecre-
tion being promoted by the antral effects of HP), its vacu-
olating toxin VacA [47-50], and upregulation of COX-
2[24,51]. Most of these studies have been able to define
this relationship based on serological data but does not
Table 1: Histological prevalence of HP and demographics of patients with colorectal neoplasms and controls
Pathology diagnosis Adenocarcinoma Adenoma Normal (Controls)
Villous Tubulovillous Tubular
Number of cases 59 20 20 19 58
Male:Female 22:37 9:11 13:7 14:6 25:33
Mean age (range) 67.55 (36–91) 73.85 (55–94) 69.45 (47–84) 66.75 (44–84) 51.60 (22–86)
HP prevalence (%positive) 10/59 16.9 1/20 5 4/20 20 4/19 21 1/58 1.7
Odds ratio (OR) (95% CI)8 . 1 3  ( 1.40–46.99)2 . 9 5  ( 0.29–9.96) 10.45 (1.52–71.52) 11.13 (1.62–76.70)
Age-sex adjusted Odds Ratio (95% CI)8 . 7 3  ( 1.01–75.48)1 . 9 4  ( 0.10–36.77)5 . 7 3  ( 1.02–112.83) 11.53 (1.12–118.98)World Journal of Surgical Oncology 2007, 5:51 http://www.wjso.com/content/5/1/51
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address direct colonisation of colorectal mucosa as a nec-
essary ingredient in the evolution of colorectal neoplasia;
indeed these theories define remote activation of colorec-
tal neoplasia by upstream HP activity and effects. Could,
for instance, in some circumstances, remote and local
effects synergise to initiate or produce these neo-
plasms[42,52]?
Experimentally, 129/SvEv Rag-2-deficient mice have been
shown to develop colitis and colonic cancer in the pres-
ence of Helicobacter. hepaticus[53], with implications relat-
ing to immune regulation in this process. More recently,
colonic adenocarcinomas have been initiated in SMAD3-
deficient mice that have been exposed to Helicobacter
infection suggesting a causal association[42].
Whereas we acknowledge that the presence of HP in our
study does not necessarily mean that local HP effects are
responsible for colorectal neoplasia, but neither does it
exclude it. It is entirely possible also that these HP organ-
Positive HP immunohistochemistry (arrowheads) is seen in gastric control material using NCL-HPp (a & b) (internal scale = 50  μm) Figure 1
Positive HP immunohistochemistry (arrowheads) is seen in gastric control material using NCL-HPp (a & b) (internal scale = 50 
μm).
Immunopositivity is seen in colorectal neoplasia using a) NCL-HPp and b) NCL-C-Jejuni (internal scale = 50 μm) Figure 2
Immunopositivity is seen in colorectal neoplasia using a) NCL-HPp and b) NCL-C-Jejuni (internal scale = 50 μm).World Journal of Surgical Oncology 2007, 5:51 http://www.wjso.com/content/5/1/51
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isms are transiting the bowel and their localisation in
colorectal neoplasia, fortuitous. We have also considered
the possibility these results could reflect identification of
HP or HP-like antigens in luminal debris: whist we can
not exclude this, our anti-HP antibody is HP-specific[54].
Clearly this pilot study needs to be progressed to molecu-
lar biological techniques such as the polymerase chain
reaction (PCR); PCR however is said to be no more sensi-
tive than routine histopathological or microbiological
techniques[32]; these methods require stringency in the
collection of diagnostic material[32].
Conclusion
We have been able to identify HP organisms in colorectal
neoplasms using immunohistochemical methods in this
pilot study. We have also been able to demonstrate an
association in their presence with tubulovillous and tubu-
lovillous adenomas and adenocarcinomas, but not with
villous adenomas. These findings need to be further sub-
stantiated with a prospective study and the use of molec-
ular biological techniques to determine a causal
association.
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